Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Gap Down – Time to Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $0.4795, but opened at $0.4642. Elite Pharmaceuticals shares last traded at $0.4796, with a volume of 210,105 shares.

Elite Pharmaceuticals Stock Down 2.0%

The business has a 50 day simple moving average of $0.57 and a 200 day simple moving average of $0.60. The company has a market capitalization of $504.99 million, a price-to-earnings ratio of 47.05 and a beta of 0.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.04 and a quick ratio of 6.34.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.